Aligos Therapeutics (ALGS) vs. Its Rivals Head-To-Head Review

Aligos Therapeutics (NASDAQ:ALGS) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Aligos Therapeutics to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, profitability, institutional ownership and risk.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Aligos Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1	0	5	1	2.86
Aligos Therapeutics Competitors	9782	15052	45296	1571	2.54

Aligos Therapeutics currently has a consensus target price of $38.50, indicating a potential upside of 710.53%. As a group, “Biotechnology” companies have a potential upside of 97.58%. Given Aligos Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Aligos Therapeutics is more favorable than its peers.

Profitability

This table compares Aligos Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-241.01%	-160.72%	-92.30%
Aligos Therapeutics Competitors	-9,046.59%	-199.78%	-30.61%

Institutional and Insider Ownership

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Aligos Therapeutics and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aligos Therapeutics	$2.19 million	-$24.19 million	-0.65
Aligos Therapeutics Competitors	$691.14 million	$10.43 million	-10.02

Aligos Therapeutics’ peers have higher revenue and earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Aligos Therapeutics has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Aligos Therapeutics’ peers have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.

Summary

Aligos Therapeutics beats its peers on 8 of the 12 factors compared.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.